Shareholder Information // Chi-Med
AIM: £39.14 (-0.36) | Nasdaq: $25.70 (+0.65)
Search
About Us
Innovation Platform
Overview
Our Pipeline
R&D Approach
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Prescription Drugs
Competitive Advantages
Main Products
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Leadership & Governance
Our Leadership
Board of Directors
Senior Management
Corporate Information
Terms of Reference & Policies
Financial Results
Overview
Financial Highlights
Chairman's Statement
Financial Reports
SEC Filings
Shareholder Information
Overview
Share Price & Chart
Major Shareholders
Events, Circulars & Forms
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
AIM Rule 26
About Us
Innovation Platform
Overview
Our Pipeline
R&D Approach
Key Corporate Partnerships
Innovation News
Commercial Platform
Overview
Prescription Drugs
Competitive Advantages
Main Products
Consumer Health
Commercial Platform News
News & Presentations
Recent News
All RNS & Press Releases
Presentations & Publications
Leadership & Governance
Our Leadership
Board of Directors
Senior Management
Corporate Information
Terms of Reference & Policies
Financial Results
Overview
Financial Highlights
Chairman's Statement
Financial Reports
SEC Filings
Shareholder Information
Overview
Share Price & Chart
Major Shareholders
Events, Circulars & Forms
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
AIM Rule 26
Shareholder Information
Chi-Med
| Shareholder Information
Share Price Chart
London AIM:HCM
£39.14
-0.36 | 15-Feb-2019 | 16:19 BST
Nasdaq:HCM
US$25.70
+0.65 | 15-Feb-2019 | 15:59 EST
Major Shareholders
Directors and Significant Shareholders
Events, Circulars and Forms
2019 Full Year Results
11 Mar 2019
WSJ Tech Health
7 Feb 2019
37th Annual J.P. Morgan Healthcare Conference
7 Jan 2019 - 10 Jan 2019
Investor FAQs
Frequently asked questions about Chi-Med's UK and US share listings
Information for Shareholders
Share-related address & contact information
AIM Rule 26 Disclosures
Disclosure reference pursuant to Rule 26 'Company Information' of the AIM Rules of Companies
Warning to Shareholders
Avoiding share fraud
Analyst Coverage
Bank of America Merrill Lynch
Canaccord Genuity
Edison
Kim Eng Securities
Panmure Gordon
Trinity Delta